Characteristics and Outcomes of Patients (pts) with Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) in Adults: A Single-Center, Prospective Analysis of 36 Pts

Conclusion: M-HLH has poor outcomes with med OS <2 mos in spite therapy. Etoposide-based therapies with or without malignancy directed therapy induced a response in approximately 30% of pts. Achieving a response to therapy was associated with improved OS. The presence of an active underlying malignancy, advanced age, and poor functional status often precluded ASCT in this population, likely contributing to dismal OS. M-HLH pts are in urgent need of more effective forms of therapy that can be administered concomitantly with cancer directed therapies. Early transition to ASCT may further improve outcomes in adult M-HLHTable.DisclosuresKadia: Jazz: Consultancy, Research Funding; BMS: Research Funding; Novartis: Consultancy; Takeda: Consultancy; Takeda: Consultancy; Abbvie: Consultancy; Celgene: Research Funding; Pfizer: Consultancy, Research Funding; Novartis: Consultancy; Pfizer: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; Abbvie: Consultancy; BMS: Research Funding; Jazz: Consultancy, Research Funding; Celgene: Research Funding. Ravandi: Macrogenix: Honoraria, Research Funding; Abbvie: Research Funding; Orsenix: Honoraria; Amgen: Honoraria, Research Funding, Speakers Bureau; Amgen: Honoraria, Research Funding, Speakers Bureau; Orsenix: Honoraria; Astellas Pharmaceuticals: Consultancy, Honoraria; Jazz: Honoraria; Seattle Genetics: Research Funding; Sunesis: Honoraria; Macrogenix: Honoraria, Research Funding; Abbvi...
Source: Blood - Category: Hematology Authors: Tags: 201. Granulocytes, Monocytes, and Macrophages: Poster III Source Type: research